Gryphon Bio, Inc.
Gryphon Bio is a clinical stage company focused on developing novel blood tests for brain health, leveraging over 20 years of -omic research to identify brain-specific biomarkers in the blood. Their mission is to improve patient lives through innovative diagnostics for various CNS diseases.
Industries
Nr. of Employees
small (1-50)
Gryphon Bio, Inc.
Products
Blood-based diagnostic tests for brain health
Diagnostic tests under development that measure brain-derived molecular signatures in blood to detect, monitor, and inform clinical decisions for CNS conditions.
Blood-based diagnostic tests for brain health
Diagnostic tests under development that measure brain-derived molecular signatures in blood to detect, monitor, and inform clinical decisions for CNS conditions.
Services
Designing and running clinical studies with patient biosampling to evaluate and refine blood tests for early detection and monitoring of brain conditions.
R&D services to discover blood-based biomarkers using multi-omics and proteomics, and to develop analytical assays with amplification-based detection where appropriate.
Use of blood-based biomarkers to enrich trial cohorts, monitor response, and de-risk drug development workflows.
Preclinical model studies and integration of neuroimaging with molecular analyses to characterize mechanisms and temporal biomarker dynamics.
Support for regulatory engagement, grant-funded program management, and generation of evidence packages to advance biomarker-based diagnostics.
Designing and running clinical studies with patient biosampling to evaluate and refine blood tests for early detection and monitoring of brain conditions.
R&D services to discover blood-based biomarkers using multi-omics and proteomics, and to develop analytical assays with amplification-based detection where appropriate.
Use of blood-based biomarkers to enrich trial cohorts, monitor response, and de-risk drug development workflows.
Preclinical model studies and integration of neuroimaging with molecular analyses to characterize mechanisms and temporal biomarker dynamics.
Support for regulatory engagement, grant-funded program management, and generation of evidence packages to advance biomarker-based diagnostics.
Expertise Areas
- Blood-based biomarker discovery
- Neuroproteomics and proteomic biomarker analysis
- Multi-omics data integration and bioinformatics
- Diagnostic assay development and validation
Key Technologies
- Proteomics
- Multi-omics
- Bioinformatics / large-scale molecular analytics
- Amplification-based molecular detection
News & Updates
Gryphon Bio, in collaboration with CURE and other institutions, received over $1.2M in funding for research on the dynamics of astrocytic activation in post-traumatic epilepsy.
Gryphon Bio, in collaboration with CURE and other institutions, received over $1.2M in funding for research on the dynamics of astrocytic activation in post-traumatic epilepsy.